OUR MISSION
mFluiDx is developing a point-of-care molecular test - the “SIMPLE CHIP” that achieves cost parity with rapid antigen tests while delivering PCR equivalent results with multiple pathogens tested at the same time. Successful deployment will allow rapid, decentralized, immediate screening on-site (small clinics, pharmacies, etc.).
GATES FOUNDATION-FUNDED TECHNOLOGY
UC BERKELEY SPIN-OUT STARTUP
note: due to IP confidentiality, schematic is not the newest prototype in development.
SIMPLE CHIP
TM
bacteria/virus/DNA/RNA molecular testing
COMPARISON
OUR TECHNOLOGY
-
Low cost: microfluidics technology enables an extremely low-cost consumable cartridge and reader instrument.
-
Multi-target testing: a single disposable cartridge can detect multiple infectious agents (viral and or bacterial) from a patient in one single test.
-
Fast: 7~15min turnaround
-
High sensitivity/specificity: we are using isothermal amplification that has equivalent performance to PCR.
-
Automated: sample-to-answer including sample prep is fully automated.
Techcrunch Battlefield Finalist
mFluiDx selected as one of the top 20 startups to pitch at Techcrunch Battlefield, from a pool of 900 startups globally. Founder and CEO- Charlie Yeh (UCSF/UC Berkeley Joint PhD in Bioengineering)
MFLUIDX'S SUPPORTERS
Spinout from the QB3 incubator startup network.
Selected to participate in Indiebio, the world's leading life science startup accelerator. Received seed funding.
Selected as top 7 startups from 87 Berkeley teams to participate in CITRIS Foundry .
Completed NSF ICORPS regional and national node for lean startup methodology training. Conducted 200+ in-person interviews in 6 U.S. states, 4 countries for product-market fit and business model validation.
Funded by SBIR Phase I and Phase II grants by NIH. Phase II final score of "1.0", ranking as top 2% of applicants.